STOCK TITAN

CytoSorbents delays Q3 2026 report for accounting review

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

CytoSorbents Corp. (CTSO) said it cannot file its Form 10-Q for the quarter ended September 30, 2026, by the prescribed deadline because it needs additional time with its independent registered public accounting firm to evaluate the calculation and accounting treatment of non-cash foreign currency exchange gains and losses recorded during the nine months ended September 30, 2026. It said it will file on or before the fifth calendar day following the prescribed due date. CTSO indicated it does not anticipate a significant change in results of operations from the corresponding period last fiscal year.

Late-filing extension Fifth calendar day CTSO said it will file its Form 10-Q on or before the fifth calendar day following the prescribed due date.
non-cash foreign currency exchange gains and losses financial
"calculation of non-cash foreign currency exchange gains and losses"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why is CTSO's 2026 third-quarter 10-Q delayed?

CTSO said it needs additional time with its independent registered public accounting firm to evaluate the calculation and accounting treatment of non-cash foreign currency exchange gains and losses recorded during the nine months ended September 30, 2026. It said it will file on or before the fifth calendar day following the prescribed due date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

OMB APPROVAL
 

OMB Number:            3235-0058

Expires:      September 30, 2028 Estimated average burden hours per response                                       2.50

  FORM 12b-25 

SEC FILE NUMBER

 

  NOTIFICATION OF LATE FILING

CUSIP NUMBER

 

 

(Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR

 

For Period Ended: September 30, 2026

¨ Transition Report on Form 10-K

¨ Transition Report on Form 20-F

¨ Transition Report on Form 11-K

¨ Transition Report on Form 10-Q

For the Transition Period Ended: ________________________________________________________________

 

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

Full Name of Registrant: CytoSorbents Corporation

 

Former Name if Applicable:

 

Address of Principal Executive Office (Street and Number): 305 College Road East 

 

City, State and Zip Code: Princeton, New Jersey 08540

 

 

 

 

 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

x 

(a)   The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 

(b)  The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

 

(c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 

 

 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

CytoSorbents Corporation (the “Company”) is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Form 10-Q”) within the prescribed time period. The Company requires additional time to work with its independent registered public accounting firm to complete its evaluation of the calculation of non-cash foreign currency exchange gains and losses recorded during the nine months ended September 30, 2026, and the related accounting treatment. As a result, the Form 10-Q cannot be filed within the prescribed time period and will be filed on or before the fifth calendar day following the prescribed due date.

 

PART IV — OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification.

 

Peter J. Mariani   (732)   329-8885
(Name)   (Area Code)   (Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
  Yes x No ¨
   
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
  Yes ¨ No x
   
  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

 

 

CytoSorbents Corporation

 

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date November 17, 2026   By /s/ Peter J. Mariani
      Peter J. Mariani
Chief Financial Officer

 

 

 

Keep reading